Extensively Drug-Resistant Tuberculosis

31  relevant articles (1 outcomes, 0 trials/studies) found for this Disease

Extremely Drug-Resistant Tuberculosis; Tuberculosis, Extremely Drug-Resistant; XDR-TB; Drug-Resistant Tuberculoses, Extensively; Drug-Resistant Tuberculoses, Extremely; Drug-Resistant Tuberculosis, Extensively; Drug-Resistant Tuberculosis, Extremely; Extensively Drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculoses; Extremely Drug Resistant Tuberculosis; Extremely Drug-Resistant Tuberculoses; Tuberculoses, Extensively Drug-Resistant; Tuberculoses, Extremely Drug-Resistant; Tuberculosis, Extensively Drug Resistant; Tuberculosis, Extremely Drug Resistant; Tuberculosis, Extensively Drug-Resistant

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Extensively Drug-Resistant Tuberculosis
2.	Tuberculosis
3.	Infection
4.	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)

Experts

1.	Amaral, L: 1 article (09/2008)
2.	Kristiansen, J E: 1 article (09/2008)
3.	Martins, M: 1 article (09/2008)
4.	Viveiros, M: 1 article (09/2008)
5.	Molnar, J: 1 article (09/2008)
6.	Jacquette, Germaine: 1 article (07/2008)
7.	Condos, Rany: 1 article (07/2008)
8.	Leibert, Eric: 1 article (07/2008)
9.	Hadgiangelis, Nicos: 1 article (07/2008)
10.	Harkin, Timothy: 1 article (07/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Extensively Drug-Resistant Tuberculosis:

1.	Rifampin (Rifampicin)FDA LinkGeneric 04/01/2008 - "This method, named "FAST-Rif" ("fluorometric assay for susceptibility testing of rifampin"), allowed the rapid, reliable, and easy detection of genotypic rifampin resistance as a marker for MDR-TB and XDR-TB." 03/18/2008 - "The analysis of the survey led to the following recommendations for strengthening TB laboratory services: (1) implementing of the published European standards for TB laboratory services with respect to infrastructure, national reference functions, biosafety, human resources, quality assurance, operational research (including evaluation of new medical diagnostics), accuracy and speed, appropriately trained staff; (2) ensuring that laboratories only perform activities for which they have demonstrated proficiency; (3) implement validated and standardised second-line drug susceptibility testing (DST), including drugs used to define extensively drug-resistant tuberculosis (XDR TB); (4) aiming to identify Mycobacterium tuberculosis complex (MTBC) and rifampicin (RIF) resistance in over 90% of cultures and cases from smear-positive sputum directly within one to two working days" 08/15/2008 - "Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both" 04/01/2008 - "The association between rifampin resistance and MDR-TB or XDR-TB makes it an important genetic marker for genotypic drug susceptibility testing" 11/15/2007 - "BACKGROUND: Recently, serious concerns about extensively drug-resistant tuberculosis (XDR-TB), which shows resistance to second-line anti-TB drugs in addition to isoniazid and rifampicin, have been raised" Order ALL the reference details at left...
2.	Isoniazid (Ftivazide)FDA LinkGeneric 11/01/2008 - "Relationship between the isoniazid-resistant mutation katGS315T and the prevalence of MDR-/XDR-TB in Osaka, Japan." 08/15/2008 - "Pre-XDR TB was defined as TB with resistance to isoniazid and rifampin and either a fluoroquinolone or second-line injectable agent but not both" 11/15/2007 - "BACKGROUND: Recently, serious concerns about extensively drug-resistant tuberculosis (XDR-TB), which shows resistance to second-line anti-TB drugs in addition to isoniazid and rifampicin, have been raised" 10/01/2008 - "Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides)" 10/01/2007 - "Currently, no information is available on the effect of resistance/susceptibility to first-line drugs different from isoniazid and rifampicin in determining the outcome of extensively drug-resistant tuberculosis (XDR-TB) patients, and whether being XDR-TB is a more accurate indicator of poor clinical outcome than being resistant to all first-line anti-tuberculosis (TB) drugs" Order ALL the reference details at left...
3.	KanamycinFDA LinkGeneric 01/01/2008 - "RESULTS: Of the 699 MDR-TB isolates submitted for testing between June 2005 and December 2006, 101 (17%) patients had a culture that was resistant to either ofloxacin or kanamycin, and 41 (6%) were resistant to both drugs (XDR-TB)" 01/01/2008 - "Patients with XDR TB were more likely to not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial susceptibility to both fluoroquinolones and kanamycin but not to streptomycin." 10/01/2008 - "Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control" 08/15/2008 - "METHODS: XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin)" 11/15/2007 - "The definition of XDR-TB was TB caused by bacilli showing resistance to both isoniazid and rifampicin and also showing resistance to any fluoroquinolone and to at least 1 of the following 3 injectable anti-TB drugs: capreomycin, kanamycin, and amikacin" Order ALL the reference details at left...
4.	Capreomycin Sulfate (Capreomycin)FDA Link 06/01/2008 - "In the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis, resistance to the injectable drug capreomycin was an independent predictor for therapy failure in this cohort" 06/01/2008 - "Among MDR- and XDR-TB cases, capreomycin resistance yielded a higher proportion of failure and death than capreomycin-susceptible cases" 10/01/2008 - "Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control" 08/15/2008 - "METHODS: XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin)" 11/15/2007 - "The definition of XDR-TB was TB caused by bacilli showing resistance to both isoniazid and rifampicin and also showing resistance to any fluoroquinolone and to at least 1 of the following 3 injectable anti-TB drugs: capreomycin, kanamycin, and amikacin" Order ALL the reference details at left...
5.	Amikacin (A.M.K)FDA LinkGeneric 10/01/2008 - "Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control" 08/15/2008 - "METHODS: XDR TB was defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin)" 11/15/2007 - "The definition of XDR-TB was TB caused by bacilli showing resistance to both isoniazid and rifampicin and also showing resistance to any fluoroquinolone and to at least 1 of the following 3 injectable anti-TB drugs: capreomycin, kanamycin, and amikacin" 03/23/2007 - "In October 2006, the World Health Organization convened an Emergency Global Task Force on XDR TB, which revised the case definition to specify resistance to at least isoniazid and rifampin among first-line anti-TB drugs, resistance to any fluoroquinolone, and resistance to at least one second-line injectable drug (amikacin, capreomycin, or kanamycin)" 02/01/2008 - "The term XDR- (extensively drug-resistant) tuberculosis (TB) has been introduced by the World Health Organisation (WHO) to characterize multi-drug-resistant MTB strains that are in vitro resistant against fluorochinolones and one of the injectible substances amikacin, capreomycin or kanamycin in addition to isoniazid and rifampin" Order ALL the reference details at left...
6.	FluoroquinolonesIBA 01/01/2008 - "The emergence of extensively drug-resistant tuberculosis (XDR-TB), that is, MDR-TB with additional bacillary resistance to the fluoroquinolones and injectables, has provided a very alarming challenge to global health, as the disease currently has a low cure rate and high mortality" 09/15/2007 - "Extensively drug resistant tuberculosis (XDR) is also resistant to more than 3 of the 6 classes of second line drugs including fluoroquinolones and aminoglycosides" 12/15/2007 - "Moreover, cases of extensively drug-resistant tuberculosis (XDR-TB) with additional resistance to fluoroquinolones and aminoglycosides are also emerging" 01/01/2008 - "Patients with XDR TB were more likely to not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial susceptibility to both fluoroquinolones and kanamycin but not to streptomycin." Order ALL the reference details at left...
7.	Streptomycin (Streptomycin Sulfate)FDA Link 01/01/2008 - "Patients with XDR TB were more likely to not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial susceptibility to both fluoroquinolones and kanamycin but not to streptomycin." 10/01/2007 - "XDR-TB cases had a relative risk (RR) of 1.58 to have an unfavourable outcome compared with MDR-TB cases resistant to all first-line drugs (isoniazid, rifampicin ethambutol, streptomycin and, when tested, pyrazinamide), and an RR of 2.61 compared with "other" MDR-TB cases (those susceptible to at least one first-line anti-TB drug among ethambutol, pyrazinamide and streptomycin, regardless of resistance to the second-line drugs not defining XDR-TB)" Order ALL the reference details at left...
8.	AminoglycosidesIBA 09/15/2007 - "Extensively drug resistant tuberculosis (XDR) is also resistant to more than 3 of the 6 classes of second line drugs including fluoroquinolones and aminoglycosides" 12/15/2007 - "Moreover, cases of extensively drug-resistant tuberculosis (XDR-TB) with additional resistance to fluoroquinolones and aminoglycosides are also emerging" Order ALL the reference details at left...
9.	linezolid (Zyvox)FDA Link 07/01/2008 - "CONCLUSIONS: Linezolid remains a promising possible addition to our therapeutic armamentarium against XDR-TB" 07/01/2008 - "Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis." 07/01/2008 - "Seven patients with confirmed MDR-TB or XDR-TB who were still culture positive despite appropriate directly observed therapy were treated with a regimen containing linezolid and at least one other active agent" 07/01/2008 - "OBJECTIVE: To determine whether linezolid is safe and well tolerated in the treatment of extensively drug-resistant tuberculosis (XDR-TB)" 10/01/2007 - "However, this general review is largely justified by the amount of data accumulated over recent years, including: i) resistant-tuberculosis epidemiology (rising incidence of multi-resistant tuberculosis in Eastern Europe, the emergence of ''extensively drug-resistant tuberculosis''); ii) latent tuberculosis standard of care (new diagnostic tests; chemoprophylaxis and workout guidelines before initiating TNF inhibitors); iii) corticosteroids in neuromeningeal tuberculosis; iv) new therapeutic options for multi-resistant tuberculosis (moxifloxacin, linezolid); v) tuberculosis treatment in HIV-infected patients; vi) discrepancies between guidelines and practices in France." Order ALL the reference details at left...
10.	butyl 3-(1H-tetrazol-5-yl)oxanilate (MTB)IBA 08/07/2007 - "New approaches are required to combat Mycobacterium tuberculosis (Mtb), especially the multi-drug resistant and extremely drug resistant organisms (MDR-TB and XDR-TB)" 02/01/2008 - "The term XDR- (extensively drug-resistant) tuberculosis (TB) has been introduced by the World Health Organisation (WHO) to characterize multi-drug-resistant MTB strains that are in vitro resistant against fluorochinolones and one of the injectible substances amikacin, capreomycin or kanamycin in addition to isoniazid and rifampin" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 12/01/2008 - "Pulmonary resection under cover of state-of-the-art chemotherapy is safe and effective for patients with localized extensively drug-resistant tuberculosis." 11/01/2008 - "Nevertheless, the emergence of extensively drug-resistant tuberculosis (XDR TB), for which chemotherapy is ineffective, has again made cytokine-based therapy attractive as one of the last available options" Order ALL the reference details at left...
2.	Directly Observed Therapy 08/15/2008 - "CONCLUSIONS: XDR TB and pre-XDR TB cases comprise a substantial fraction of MDR TB cases in California, indicating the need for interventions that improve surveillance, directly observed therapy, and rapid drug susceptibility testing and reporting." 10/01/2008 - "Inadequate global tuberculosis control through the directly observed therapy short course strategy alone and the growing threat of multidrug-resistant and extensively drug-resistant tuberculosis has driven recent development of new commercial and noncommercial tests, which are most desperately needed in resource-limited, high-burden settings" 07/01/2008 - "Seven patients with confirmed MDR-TB or XDR-TB who were still culture positive despite appropriate directly observed therapy were treated with a regimen containing linezolid and at least one other active agent" Order ALL the reference details at left...
3.	Therapeutics 10/01/2008 - "To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed." 04/01/2008 - "The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics." Order ALL the reference details at left...
4.	Chemoprevention 10/01/2007 - "However, this general review is largely justified by the amount of data accumulated over recent years, including: i) resistant-tuberculosis epidemiology (rising incidence of multi-resistant tuberculosis in Eastern Europe, the emergence of ''extensively drug-resistant tuberculosis''); ii) latent tuberculosis standard of care (new diagnostic tests; chemoprophylaxis and workout guidelines before initiating TNF inhibitors); iii) corticosteroids in neuromeningeal tuberculosis; iv) new therapeutic options for multi-resistant tuberculosis (moxifloxacin, linezolid); v) tuberculosis treatment in HIV-infected patients; vi) discrepancies between guidelines and practices in France." Order ALL the reference details at left...
5.	Magic 03/01/2007 - "From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis." Order ALL the reference details at left...